The polypill: At what price would it become cost effective?

Journal of Epidemiology and Community Health

Volumn 60, Issue 3, 2006, Pages 213-217

  Franco, Oscar H ^a   Steyerberg, Ewout W ^a   De Laet, Chris ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

COST; PRICE DYNAMICS;

ADULT; AGED; ARTICLE; CALCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PILL; PRIMARY HEALTH CARE; SENSITIVITY ANALYSIS; STROKE;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PUBLIC HEALTH; UNITED STATES;

EID: 33344455605     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2005.040253     Document Type: Article

References (23)

1. Jacobson TA. Clinical context: current concepts of coronary heart disease management. Am J Med 2001;110(suppl 6A):3-11S.
2. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002;324:1570-6.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
4. Messori A, Santarlasci B, Trippoli S, et al. "Polypill" to fight cardiovascular disease: cost-effectiveness of statins for primary prevention of cardiovascular events is questionable. BMJ 2003;327:808-9.
5. Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003;327:1264.
6. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham study. Am J Public Health 1951;41:279-81.
7. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979;110:281-90.
8. Cupples LA, D'Agostino RB, Anderson K, et al. Comparison of baseline and repeated measure covariate techniques in the Framingham heart study. Stat Med 1988;7:205-22.
9. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
10. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) full report. http://circ.ahajournals.org/cgi/reprint/106/25/3143.pdf (accessed 4 Jun 2005).
11. Euro-medicines. http://www.euromedicines.org (accessed 20 Mar 2005).
12. Gezondheidszorg CT. http://www.ctgzorg.nl, (accessed 20 Mar 2005).
13. Farmacotherapeutisch Kompas. Medisch farmaceuthische voorlichting/uitgave van de Commissie Farmaceuthische hulp van het College voor zorgverzerkeringen. Amstelveen: Farmacotherapeutisch Kompas, 2003.
14. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 2001;22:751-61.
15. Health Insurance Council Report. Dutch guidelines for pharmacoeconomic research. Amstelveen: Health Insurance Council, 1999.
16. Hunink MGM, Glasziou PP, Siegel JE, et al. Decision making in health and medicine: interpreting evidence and values. Cambridge, England: Cambridge University Press, 2001.
17. Laupacis A, Feeny D, AS Detsky et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
18. Mark D. Medical economics in cardiovascular medicine. In: Topol EJ, eds. Textbook of cardiovascular medicine. New York: Lippincott-Raven, 1997.
19. Hvad er Danmarks Statistikbank. http://www.statistikbanken.dk (accessed 10 Dec 2004).
20. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
21. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162:2197-202.
22. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
23. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.